Article: Nonsurgical treatment of Dupuytren's contracture: 1-year US post-marketing safety data for collagenase clostridium histolyticum

Background: Collagenase clostridium histolyticum (CCH) is a Food and Drug Administration-approved treatment for adult patients with Dupuytren's contracture with a palpable cord that has been shown efficacious and safe in clinical trials.

Methods: This paper summarizes the most common post-marketing clinical adverse event (AE) reports received by the manufacturer of CCH and sponsor of the US Biologics License Application (Auxilium Pharmaceuticals, Malvern, PA, USA) during the first 12 months after drug approval and commercialization in the USA.

Results: Of the 115 AE reports describing 270 AEs voluntarily received from patients or health care providers after approximately 5,400 injections of CCH administered, the most common AEs involved local, nonserious reactions to treatment, including skin tears, peripheral edema, and contusion. There were few serious AEs observed (0.6% reporting rate per 1,000 injections), and two flexor tendon ruptures and one flexor pulley injury were reported.

Conclusions: Analysis of post-marketing AEs received for CCH in the first year post-approval supports the safety profile reported earlier during clinical development and did not reveal additional clinical risks or concerns about CCH.

Citing Articles

Incidence of Tendon Rupture After Collagenase Clostridium Histolyticum Injection for Treatment of Dupuytren Contracture in Adults: A Postmarketing Safety Analysis.

Peimer C, Hurley D, Latch T, Scott S, Pess G J Hand Surg Glob Online. 2023; 5(1):33-38.

PMID: 36704373 PMC: 9870809. DOI: 10.1016/j.jhsg.2022.08.013.

Dupuytren's interventions surgery versus collagenase (DISC) trial: study protocol for a pragmatic, two-arm parallel-group, non-inferiority randomised controlled trial.

Dias J, Arundel C, Tharmanathan P, Keding A, Welch C, Corbacho B Trials. 2021; 22(1):671.

PMID: 34593024 PMC: 8481756. DOI: 10.1186/s13063-021-05595-w.

Complications Following Collagenase Treatment for Dupuytren Contracture.

Wozniczka J, Canepa C, Mirarchi A, Solomon J Hand (N Y). 2017; 12(5):NP148-NP151.

PMID: 28635316 PMC: 5684954. DOI: 10.1177/1558944717711461.

A new bromelain-based enzyme for the release of Dupuytren's contracture: Dupuytren's enzymatic bromelain-based release.

Rubin G, Rinott M, Wolovelsky A, Rosenberg L, Shoham Y, Rozen N Bone Joint Res. 2016; 5(5):175-7.

PMID: 27174554 PMC: 4921045. DOI: 10.1302/2046-3758.55.BJR-2016-0072.

Identification of putative drug targets for human sperm-egg interaction defect using protein network approach.

Sabetian S, Shamsir M BMC Syst Biol. 2015; 9:37.

PMID: 26187737 PMC: 4506605. DOI: 10.1186/s12918-015-0186-7.

References

1.

Starkweather K, Lattuga S, HURST L, Badalamente M, Guilak F, Sampson S . Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am. 1996; 21(3):490-5. DOI: 10.1016/S0363-5023(96)80368-6. View

2.

Hurst L, Badalamente M, Hentz V, Hotchkiss R, Kaplan F, Meals R . Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009; 361(10):968-79. DOI: 10.1056/NEJMoa0810866. View

3.

French M, Mookhtiar K, Van Wart H . Limited proteolysis of type I collagen at hyperreactive sites by class I and II Clostridium histolyticum collagenases: complementary digestion patterns. Biochemistry. 1987; 26(3):681-7. DOI: 10.1021/bi00377a004. View

4.

Ahmad S . Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med. 2003; 18(1):57-60. PMC: 1494803. DOI: 10.1046/j.1525-1497.2003.20130.x. View

5.

Denkler K . Surgical complications associated with fasciectomy for dupuytren's disease: a 20-year review of the English literature. Eplasty. 2010; 10:e15. PMC: 2828055. View

6.

Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N . Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010; 35(12):2027-38.e1. DOI: 10.1016/j.jhsa.2010.08.007. View

7.

Chen N, Srinivasan R, Shauver M, Chung K . A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture. Hand (N Y). 2012; 6(3):250-5. PMC: 3153627. DOI: 10.1007/s11552-011-9326-8. View

8.

Hutchison R, Rayan G . Astley Cooper: his life and surgical contributions. J Hand Surg Am. 2011; 36(2):316-20. DOI: 10.1016/j.jhsa.2010.10.036. View

9.

Zhang A, Curtin C, Hentz V . Flexor tendon rupture after collagenase injection for Dupuytren contracture: case report. J Hand Surg Am. 2011; 36(8):1323-5. DOI: 10.1016/j.jhsa.2011.05.016. View

10.

Desai S, Hentz V . Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opin Biol Ther. 2010; 10(9):1395-404. DOI: 10.1517/14712598.2010.510509. View

11.

Elliot D . The early history of contracture of the palmar fascia. Part 2: The revolution in Paris: Guillaume Dupuytren: Dupuytren's disease. J Hand Surg Br. 1988; 13(4):371-8. DOI: 10.1016/0266-7681_88_90158-1. View

Nonsurgical Treatment of Dupuytren's Contracture: 1-year US Post-marketing Safety Data for Collagenase Clostridium Histolyticum